Nintedanib Esylate

乙磺酸尼达尼布

Report date: 2026/03/23 20:03:44
NMEFirst In Class

Base Information

Drug NameNintedanib Esylate
Drug Alias NameIntedanib宁替达尼宁特达尼nintedanib尼达尼布 +[11] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionFibroblast growth factor receptor 3 antagonistsVascular endothelial growth factor receptor 3 antagonistsFibroblast growth factor receptor 1 antagonists +[10] 
TargetsVascular endothelial growth factor receptor 1Vascular endothelial growth factor receptor 3Platelet-derived growth factor receptor beta +[10] 
Therapy Area/IndicationsRejection of lung transplantationSolid tumourssystemic sclerosis-associated interstitial lung disease +[43] 
Global Approved IndicationsIdiopathic Pulmonary FibrosisCarcinoma, Non-Small-Cell Lung
Approved Indications in ChinaIdiopathic Pulmonary Fibrosis
Original Approved Country/TerritoryUnited States
Original Approved Date2014/10/15
Country/TerritoryCzechiaBelgiumBosnia and Herzegovina +[59] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesC.H. Boehringer Sohn Ag & Co. Kg
China Registration ClassN/A

Develop Information

Active CompaniesC.H. Boehringer Sohn Ag & Co. KgRoswell Park Cancer InstituteBoehringer Ingelheim Pharma Gmbh & Co Kg +[8] 
Inactive CompaniesCentro Nacional De Investigaciones OncológicasWake Forest University Health SciencesMartin-Luther-Universitat Halle-Wittenberg +[11] 
Active Indicationssystemic sclerosis-associated interstitial lung diseaseTelangiectasia, Hereditary HemorrhagicIdiopathic Pulmonary Fibrosis +[10] 
Inactive IndicationsRejection of lung transplantationSolid tumoursScleroderma, Systemic +[33] 

Other Information

ATC CodeL01EX09
Related LinksWikipediaDrugBankKEGG